Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Am Acad Dermatol. 2015 Dec 11;74(2):370–371. doi: 10.1016/j.jaad.2015.09.073

Figure 2. Decrease in serum CXCL10 after initiating treatment with ruxolitinib.

Figure 2

Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA). CXCL10 level was elevated and remained stable while the patient was taking placebo in the first trial, but decreased after initiating treatment with ruxolitinib.